Thomas H Lane

US Patent:

8258266, Sep 4, 2012

Filed:

May 27, 2009

Appl. No.:

12/472877

Inventors:

Shrikant Deshpande - Fremont CA, US
Haichun Huang - Fremont CA, US
Mohan Srinivasan - Cupertino CA, US
Josephine M. Cardarelli - San Carlos CA, US
Changyu Wang - Fremont CA, US
David B. Passmore - San Carlos CA, US
Vangipuram Rangan - Pleasant Hill CA, US
Thomas E. Lane - Irvine CA, US
Hans S. Keirstead - Irvine CA, US
Michael T. Liu - Irvine CA, US

Assignee:

Medarex, Inc. - Princeton NJ

International Classification:

C07K 16/00
C12P 21/08
A61K 39/395
A61K 39/40
C12N 5/02
C12N 5/16
C07K 1/00

US Classification:

5303871, 5303873, 5303879, 5303881, 53038815, 5303882, 53038823, 5303911, 4241301, 4241321, 4241341, 4241361, 4241391, 4241411, 4241421, 4241581, 4241781, 435325, 435326, 435328, 435331, 435335

Abstract:

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.

US Patent:

20020107777, Aug 8, 2002

Filed:

Feb 6, 2001

Appl. No.:

09/778053

Inventors:

Thomas Lane - San Clemente CA, US
Robert Venter - Laguna Niguel CA, US

International Classification:

G06F017/60
G06F007/00
G06F017/00

US Classification:

705/037000, 707/104100, 705/028000

Abstract:

A service provider enters into a contractual relationship with a law enforcement agency to be their exclusive agent for auctioning seized property over the Internet. The service provider establishes a secure area for receiving, processing, and handling the seized property from the law enforcement agency. Seized items are received in the secure area, photographed, inventoried, and entered into the service provider inventory database. Appraisers evaluate each seized item, set a price for each seized item, prepare each seized item for posting, and post each seized item for auction on an Internet auction web site. The seized items are then auctioned off on the Internet web site. The winning bids are processed and payment collected. Sold items are then staged for shipping, removed from the inventory database, and then shipped to each winning bidder.

US Patent:

20040096446, May 20, 2004

Filed:

Nov 12, 2003

Appl. No.:

10/344833

Inventors:

Thomas Lane - Irvine CA, US

International Classification:

A61K039/395

US Classification:

424/145100

Abstract:

The invention provides a method of reducing the severity and reversing the neurological effects of a demyelinating disease in a subject by administering to a subject having a demyelinating disease an effective amount of a neutralizing agent specific for interferon inducible protein of 10 kDa (IP-10). The methods of the invention promote remyelination of demyelinated nerve fibers and impede further demyyelination of nerve fibers in a subject affected with a demyelinating disease by administering to a subject having a demyelinating disease.

US Patent:

20050025744, Feb 3, 2005

Filed:

Jul 29, 2004

Appl. No.:

10/903118

Inventors:

Thomas Lane - Irvine CA, US

International Classification:

A61K039/395
A61K038/21

US Classification:

424085600, 424145100, 514002000

Abstract:

The invention discloses methods and compositions for treating Multiple Sclerosis through the administration of humanized anti-IP-10 antibody in combination with an additional therapeutic compound.

US Patent:

20050053600, Mar 10, 2005

Filed:

Sep 9, 2004

Appl. No.:

10/938673

Inventors:

Thomas Lane - Irvine CA, US

International Classification:

A61K039/395

US Classification:

424141100, 424146100

Abstract:

The invention discloses methods and compositions for treating rheumatoid arthritis through the administration of humanized anti-IP-10 antibody alone or in combination with an additional anti-rheumatic therapeutic compound.

US Patent:

20050191293, Sep 1, 2005

Filed:

Dec 10, 2004

Appl. No.:

11/009731

Inventors:

Shrikant Deshpande - Freemont CA, US
Haichun Huang - Fremont CA, US
Mohan Srinivasan - Cupertino CA, US
Josephine Cardarelli - San Carlos CA, US
Changyu Wang - Fremont CA, US
David Passmore - Mountain View CA, US
Vangipuram Rangan - Pleasant Hill CA, US
Thomas Lane - Irvine CA, US
Hans Keirstead - Irvine CA, US
Michael Liu - Irvine CA, US

International Classification:

A61K039/395
C07K016/28

US Classification:

424143100, 530388220

Abstract:

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.

US Patent:

20080019973, Jan 24, 2008

Filed:

Jul 29, 2003

Appl. No.:

10/549482

Inventors:

Thomas E. Lane - Irvine CA, US
Daniela J.J. Carr - Edmond OK, US

International Classification:

A61K 39/395
A01K 67/00
C07K 16/24
C12Q 1/18
C12Q 1/68
G01N 33/53

US Classification:

4241451, 435 32, 435 6, 435 792, 800 9

Abstract:

The invention provides a method of reducing ocular inflammation in an individual susceptible to ocular inflammation. The method involves administering to the individual an effective amount of a neutralizing agent specific for CXCL10. Also provided is a method for reducing spread of viral infection within ocular tissues of an individual susceptible to ocular viral infection, which involves administering to the individual an effective amount of a neutralizing agent specific for CXCL10. Further provided is a method of extending corneal graft survival following corneal transplantation in an individual, which involves administering to said individual an effective amount of a neutralizing agent specific for CXCL10. Additionally, the invention provides a method for identifying a compound for reducing ocular inflammation in an animal.

US Patent:

20120230998, Sep 13, 2012

Filed:

May 23, 2012

Appl. No.:

13/478786

Inventors:

Shrikant DESHPANDE - Fremont CA, US
Haichun HUANG - Fremont CA, US
Mohan SRINIVASAN - Cupertino CA, US
Josephine M. CARDARELLI - San Carlos CA, US
Changyu WANG - Fremont CA, US
David PASSMORE - Mountain View CA, US
Vangipuram RANGAN - Pleasant Hill CA, US
Thomas E. LANE - Irvine CA, US
Hans S. KEIRSTEAD - Irvine CA, US
Michael T. LIU - Irvine CA, US

Assignee:

MEDAREX, INC. - Princeton NJ

International Classification:

A61K 39/395
A61P 25/00
A61P 19/02
A61P 29/00
A61P 1/00
A61P 9/10
A61P 17/00
A61P 11/00
A61P 25/28
A61K 48/00
A61P 13/12
C12N 5/02
A61P 3/10

US Classification:

4241351, 435375, 4241391, 4241331

Abstract:

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.